Magnetically based nanocarriers in drug delivery

Denkbaş, Emir Baki; Çelik, Ekin; Erdal, Ebru; Kavaz, Doğa; Vural, Oznur Akbal; Kara, Göknur; Bayram, Cem

doi:10.1016/b978-0-323-42866-8.00009-5

Cited by 20 publications

(20 citation statements)

References 258 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The size and magnetic properties of synthesized MNPs are dependent on the physiological characteristics of the targeted organ [ 76 ]. Including their magnetic properties, the attractive characteristics of MNPs which include biocompatibility, low toxicity, easily modifiable surfaces have sprouted interest in drug delivery research [ 77 ]. Furthermore, since they can bind to several compounds such as drugs, antibodies and proteins, they can be directed to different receptors using an external magnetic field [ 77 ].…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

“…Including their magnetic properties, the attractive characteristics of MNPs which include biocompatibility, low toxicity, easily modifiable surfaces have sprouted interest in drug delivery research [ 77 ]. Furthermore, since they can bind to several compounds such as drugs, antibodies and proteins, they can be directed to different receptors using an external magnetic field [ 77 ]. Despite mounting in vitro and in vivo data that indicate the potential applications of MNPs and other nano formulations, only a very few clinical trials have assessed their efficacy and safety on CNS conditions such as depression [ 77 ].…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

“…Furthermore, since they can bind to several compounds such as drugs, antibodies and proteins, they can be directed to different receptors using an external magnetic field [ 77 ]. Despite mounting in vitro and in vivo data that indicate the potential applications of MNPs and other nano formulations, only a very few clinical trials have assessed their efficacy and safety on CNS conditions such as depression [ 77 ]. A study that was done using iron oxide nanoparticles proved that they are biocompatible and highly biodegradable under in vivo conditions.…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

“…The group concluded that the use of magnetic nanoparticles could enhance the drug loading capacity and the sustained release profile of the formulation [ 46 ]. A previous study displayed that MNPs might be cleared by macrophages before reaching the targeted receptor or organ and the nanoparticles tend to aggregate due to strong magnetic interactions [ 77 ] which might result in increased toxicity and tissue damage. Moreover, in the absence of surface coating, the MNPs are prone to oxidation which may lead to the loss of magnetic field properties.…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

See 3 more Smart Citations

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

Nanotechnology has aided in the advancement of drug delivery for the treatment of several neurological disorders including depression. Depression is a relatively common mental disorder which is characterized by a severe imbalance of neurotransmitters. Several current therapeutic regimens against depression display drawbacks which include low bioavailability, delayed therapeutic outcome, undesirable side effects and drug toxicity due to high doses. The blood–brain barrier limits the entry of the drugs into the brain matrix, resulting in low bioavailability and tissue damage due to drug accumulation. Due to their size and physico-chemical properties, nanotechnological drug delivery systems present a promising strategy to enhance the delivery of nanomedicines into the brain matrix, thereby improving bioavailability and limiting toxicity. Furthermore, ligand-complexed nanocarriers can improve drug specificity and antidepressant efficacy and reduce drug toxicity. Biopolymers and nanocarriers can also be employed to enhance controlled drug release and reduce the hepatic first-pass effect, hence reducing the dosing frequency. This manuscript reviews recent advances in different biopolymers, such as polysaccharides and other nanocarriers, for targeted antidepressant drug delivery to the brain. It probes nano-based strategies that can be employed to enhance the therapeutic efficacy of antidepressants through the oral, intranasal, and parenteral routes of administration.

show abstract

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

See 2 more Smart Citations

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Magnetic barium hexaferrite (BaFe

) nanoparticles have been investigated in high-frequency applications due to their high magnetic anisotropy, among other reasons [ 17 ]. In other works, magnetic particles have been studied for targeting and destroying cancer cells [ 18 , 19 , 20 , 21 ]. Most in vitro studies were performed in low-viscosity fluids, which ranged from

Pa·s, such as water, model bodily fluids, cell culture fluids, or alcohol [ 6 , 7 , 9 , 11 , 12 , 17 , 18 , 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Optical Imaging of Magnetic Particle Cluster Oscillation and Rotation in Glycerol

et al. 2021

View full text Add to dashboard Cite

Magnetic particles have been evaluated for their biomedical applications as a drug delivery system to treat asthma and other lung diseases. In this study, ferromagnetic barium hexaferrite (BaFe12O19) and iron oxide (Fe3O4) particles were suspended in water or glycerol, as glycerol can be 1000 times more viscous than water. The particle concentration was 2.50 mg/mL for BaFe12O19 particle clusters and 1.00 mg/mL for Fe3O4 particle clusters. The magnetic particle cluster cross-sectional area ranged from 15 to 1000 μμm2, and the particle cluster diameter ranged from 5 to 45 μμm. The magnetic particle clusters were exposed to oscillating or rotating magnetic fields and imaged with an optical microscope. The oscillation frequency of the applied magnetic fields, which was created by homemade wire spools inserted into an optical microscope, ranged from 10 to 180 Hz. The magnetic field magnitudes varied from 0.25 to 9 mT. The minimum magnetic field required for particle cluster rotation or oscillation in glycerol was experimentally measured at different frequencies. The results are in qualitative agreement with a simplified model for single-domain magnetic particles, with an average deviation from the model of 1.7 ± 1.3. The observed difference may be accounted for by the fact that our simplified model does not include effects on particle cluster motion caused by randomly oriented domains in multi-domain magnetic particle clusters, irregular particle cluster size, or magnetic anisotropy, among other effects.

show abstract